


Factsheet 2023



Company description

Formycon is a leading, independent developer of high-quality biopharmaceutical medicines, especially biosimilars. The company focuses on treatments in ophthalmology, immunology and immuno-oncology, as well as other major chronic diseases, covering the entire value chain from technical development to Phase III clinical trials and the preparation of dossiers for marketing approval. Formycon currently has six biosimilars in development. Based on its extensive experience in the development of biopharmaceutical drugs, the company is also working on the development of a COVID-19 drug FYB207.

Development pipeline

Biosimilar Candidate	Reference (INN)	Disease Area	Preclinical Phase	Clinical Phase I	Clinical Phase III	Filing	Approval	
FYB201	LUCENTIS®	Ophthalmology	[Progress bar]					
FYB202	STELARA®	Immunology	[Progress bar]	[Progress bar]				
FYB203	EYLEA®	Ophthalmology	[Progress bar]					
FYB206	KEYTRUDA®	Immuno-oncology	[Progress bar]					
FYB208	undisclosed	undisclosed	[Progress bar]					
FYB209	undisclosed	undisclosed	[Progress bar]					
Produkt	Innovation	Disease Area	Preclinical Phase	Clinical Phase I-III	Filing	Approval		
FYB207	Innovative Product	COVID-19	[Progress bar]					

Strategy and goals

Through their proven efficacy, cost-efficiency and high quality standard, biosimilars make an important contribution to providing patients with access to effective medical treatments. At the same time, they help to reduce the financial burden on global healthcare systems.

With the 2022 launch of FYB201 in the U.S., Europe and the U.K. – with additional filings planned in 2023 – the company has become a commercial-stage biotech company focused on biosimilars. Through the transaction with ATHOS KG (Family Office Strüngmann) in spring 2022 with the acquisition of the biosimilar asset FYB201 at 50% and of the biosimilar asset FYB202 at 100%, the stage has also been set for a significant increase of the participation in future marketing revenues. Formycon plans to primarily invest the resulting cash inflows into the expansion of its product development pipeline growing towards becoming a fully integrated pharmaceutical company in the biosimilar segment.

Facts

Founded: 2012
 Headquarters: Planegg / Munich
 Employees: > 200

Management

Dr. Stefan Glombitza (Board CEO),
 Nicola Mikulcik (Board CBO), Dr. Andreas Seidl
 (Board CSO), Dr. Nicolas Combé (CFO)

Supervisory Board

Dr. Olaf Stiller (Chairman), Peter Wendeln
 (Deputy Chairman), Klaus Röhrig (Member),
 Dr. Thomas Strüngmann (Member)

Financial calendar

April 27, 2022
 Publication of Annual Report 2022

June 2023
 Statement Q1 Figures 2023

July 25, 2023
 Annual General Meeting

September 2023
 Publication of Half-Year Report 2023

November 2023
 Statement Nine-Month Figures 2023

Extract press releases

February 7, 2023
 Enno Spillner appointed Chief Financial Officer
 (CFO) of Formycon AG

February 6, 2023
 Aflibercept Biosimilar Candidate FYB203 shows
 comparable efficacy to the reference product
 Eylea® in Phase III Study

February 2, 2023
 Formycon and Fresenius Kabi conclude global
 commercialization partnership for FYB202, a
 biosimilar candidate to Stelara® (ustekinumab)

February 2, 2023
 Formycon AG announces result of private
 placement and sets placement price for the new
 shares from the capital increase

January 9, 2023
 Formycon announces binding Term Sheet
 between Klinge Biopharma and Coherus
 BioSciences for the exclusive commercialization
 of FYB203, a biosimilar candidate to Eylea®, in
 the United States

[Read more](#)

Key financials (in € million)

	2018	2019	2020	2021
Revenue	43.0	33.2	34.2	37.0
EBITDA	7.1	-1.4	-4.8	-12.4
Net Income	7.1	-2.3	-5.9	-13.5
Equity Ratio (in %)	83.9	90.0	90.0	85.0

Market data

ISIN: DE000A1EWVY8
 Market Segment: Frankfurt, Stock Exchange „Scale“
 Market Capitalization: ~ 1,3 Mrd. Euro
 Outstanding Shares: 16.038.775

Shareholder Structure

26,7 % ATHOS KG
 14,9 % Wendeln & Cie. KG
 6,7 % Active Ownership Corporations S.á.r.l
 5,5 % DSP Beteiligungsgesellschaft GmbH & Co. KG
 6,5 % Founders and Management
 36,7 % Free Float

Contact

Sabrina Müller | Corporate Communications & Investor Relations
 +49 89 86 46 67 149 | sabrina.mueller@formycon.com

This document may contain forward-looking statements and information which are based on our current expectations and certain assumptions. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, performance of the company, development of the products and the estimates given here. Such known and unknown risks and uncertainties comprise, among others, the research and development, the regulatory approval process, the timing of the actions of regulatory bodies and other governmental authorities, clinical results, changes in laws and regulations, product quality, patient safety, patent litigation, contractual risks and dependencies from third parties. With respect to pipeline products, Formycon AG does not provide any representation, warranties or any other guarantees that the products will receive the necessary regulatory approvals or that they will prove to be commercially exploitable and/or successful. Formycon AG assumes no obligation to update these forward-looking statements or to correct them in case of developments which differ from those anticipated. This document neither constitutes an offer to sell nor a solicitation of an offer to buy or subscribe for securities of Formycon AG. No public offering of securities of Formycon AG will be made nor is a public offering intended. This document and the information contained therein may not be distributed in or into the United States of America, Canada, Australia, Japan or any other jurisdictions, in which such offer or such solicitation would be prohibited. This document does not constitute an offer for the sale of securities in the United States.